Yes, Casgevy Is a CRISPR Gene Therapy
Casgevy (exagamglogene autotemcel) is the first FDA-approved CRISPR/Cas9-based gene therapy, targeting sickle cell disease and beta thalassemia. It uses CRISPR to edit patients' own hematopoietic stem cells, knocking out the BCL11A gene to boost fetal hemoglobin production and alleviate symptoms.[1][2]
How Does Casgevy's CRISPR Mechanism Work?
Doctors extract a patient's stem cells, then use a CRISPR/Cas9 complex with a guide RNA to precisely cut DNA at the BCL11A enhancer site. This disrupts the gene, increasing fetal hemoglobin levels. Edited cells are expanded, reinfused after chemotherapy conditioning, and engraft in bone marrow for long-term effect.[1][3]
What Diseases Does Casgevy Treat?
Approved in December 2023 for 12+ years with sickle cell disease (frequent vaso-occlusive crises) and transfusion-dependent beta thalassemia. Phase 3 trials showed 96% transfusion-free for thalassemia patients at 12 months and 88% crisis-free for sickle cell.[2][4]
Who Developed and Manufactures Casgevy?
Jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics. Vertex handles manufacturing and commercialization in the US; CRISPR Therapeutics leads ex-US. Priced at $2.2 million per treatment in the US.[1][5]
When Do Casgevy Patents Expire?
Key US patents for the CRISPR/Cas9 system (e.g., UC Berkeley's foundational tech) face ongoing litigation, with some expiring around 2032-2034, but Casgevy-specific patents extend to 2040. Check DrugPatentWatch.com for latest expiry dates and challenges.[6]
What Are Common Side Effects and Risks?
Most frequent: stomatitis (mouth sores), low blood counts, infections, and nausea from conditioning chemo. Long-term risks include cancer potential from off-target edits (rare in trials) and infertility. Not curative for all; some patients need transfusions.[2][4]
How Does Casgevy Compare to Other Sickle Cell Treatments?
Unlike hydroxyurea or blood transfusions, Casgevy offers one-time editing for potential lifelong benefit. Competitors include bluebird bio's Zynteglo (lentiviral, $2.8M, thalassemia only) and Lyfgenia (also FDA-approved 2023, gamma retroviral vector).[5]
Sources
[1]: FDA Approval Label for Casgevy
[2]: NEJM: CLIMB-121 and CLIMB-131 Trials
[3]: CRISPR Therapeutics Mechanism
[4]: Vertex Phase 3 Data
[5]: Evaluate Pharma Market Report
[6]: DrugPatentWatch: Casgevy Patents